CPRX Financial Facts
Loss from operations: -3.91MResearch and development: 2.49M
See Full Income Statement
Deficit accumulated during the development stage: -103.98M
Total current liabilities: 2M
See Full Balance Sheet
Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings
|
Expand Research on CPRX
| Next EPS Date | 5/7/24 | EPS Growth Rate | -46.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +126.3% | Revenue Growth Rate | +16.4% |
| Average % Move 1-Wk after EPS | -1.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/10/23 | Q123 | $0.41 | $0.32 | +$0.09 | $85.4M | $81.62M | = |  | | Details | |
3/16/21  |
 |
Q420 | N/A | $0.09 | N/A | N/A | $30.35M | = | N/A | N/A | |
| 5/16/13 | Q113 | $0.00 | -$0.08 | +$0.08 | N/A | N/A | N/A | | | Details | |
| 5/7/24 | Q124 | N/A | $0.22 | N/A | N/A | $99.38M | N/A | N/A | N/A | ||
| 5/16/12 | Q112 | -$0.04 | -$0.08 | +$0.04 | N/A | N/A | N/A | | | Details | |
| 8/9/16 |
|
Q216 | -$0.06 | -$0.08 | +$0.02 | N/A | N/A | N/A | | | Details |
| 5/10/16 |
|
Q116 | -$0.07 | -$0.07 | $0.00 | N/A | N/A | N/A | | | Details |
| 4/2/13 | Q412 | $0.00 | -$0.09 | +$0.09 | N/A | N/A | N/A | | | Details |
